Gilead Sciences stock last at EUR 131.59 at Lang & Schwarz close
Published on 10/02/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock was last recorded at EUR 131.59 at the Lang & Schwarz close on October 1, 2026.
Trading reference
The next price is shown from the start of trading by the continuously updated real-time quote of Gilead Sciences stock.
Lenacapavir access planning
In a September 16, 2026 release, Gilead Sciences said it had expanded six royalty-free voluntary licensing agreements to include investigational once-yearly lenacapavir for HIV prevention as pre-exposure prophylaxis. The agreements cover 120 high-incidence countries, primarily low- and lower-middle-income countries, and are intended to support manufacturing readiness, technology transfer and future supply planning while the Phase 3 PURPOSE 365 trial continues.
Regional partnership
Gilead said in a September 15, 2026 release that it had reached an agreement with the Pan American Health Organization to accelerate access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean. The company said the agreement creates an access pathway for 14 countries outside its voluntary licensing agreements, including Brazil, Mexico and Peru, through PAHO’s Regional Revolving Funds. Gilead Sciences said the partnership forms part of its broader global access strategy for lenacapavir.
